Skip to content
    MOH
    Earnings call· Mar 2026(Q1 FY26)

    MOLINA HEALTHCARE Q1 FY26 earnings call MOH

    Apr 23, 2026 Source

    Executive summary

    Molina Healthcare Q1 FY26 — Solid Start, Reaffirmed Guidance Amidst Evolving Trends

    Molina Healthcare reported solid Q1 FY26 results with strong MCR and adjusted EPS of $2.35. Despite positive indicators across all segments, management prudently reaffirmed full-year guidance, citing the need for more time-tested data following 2025's volatile medical cost environment. The company is navigating increased Medicaid attrition and the exit of its MAPD product, while focusing on its duals business and the implementation of the Florida CMS contract.

    Highlights

    5
    • Adjusted EPS of $2.35, exceeding internal and external expectations.

    • Consolidated MCR of 91.1% reflecting strong operating performance.

    • Parent company cash balance expected to reach over $600 million by year-end from subsidiary dividends.

    • Medicare Duals business (HIDE/FIDE) off to a good start, performing better than anticipated.

    • Medicaid medical cost trend was modestly favorable to expectations in Q1, with the 2.5% acuity shift from 2025 not recurring.

    Concerns

    3
    • Increased Medicaid membership attrition forecast to a 6% decline for FY26 (up from prior 2% guidance).

    • MAPD product expected to be a $1.00 EPS drag in FY26, leading to its exit in 2027.

    • Debt at 6.1x trailing 12-month EBITDA, above the long-term target of low 40s for debt-to-capital.

    Guidance & targets

    15
    CategoryTargetConfidence
    Full-year 2026 adjusted EPS
    at least $5
    high materiality
    High
    Full-year 2026 premium revenue
    approximately $42 billion
    high materiality
    High
    Full-year 2026 Medicaid same-store membership decline
    6%
    medium materiality
    Medium
    Full-year 2026 Medicaid ending members
    approximately 4.5 million
    medium materiality
    Medium
    Full-year 2026 Marketplace ending members
    approximately 250,000
    medium materiality
    Medium
    Full-year 2026 consolidated MCR
    unchanged
    high materiality
    High
    Full-year 2026 Medicaid MCR
    92.9%
    high materiality
    High
    Full-year 2026 Medicare MCR
    94%
    high materiality
    High
    Full-year 2026 Marketplace MCR
    85.5%
    high materiality
    High
    Full-year 2026 G&A ratio
    approximately 6.4%
    medium materiality
    High
    Full-year 2026 Medicaid medical cost trend
    5%
    high materiality
    High
    Full-year 2026 Medicaid rate increases
    4%
    high materiality
    High
    Long-term margin expansion
    clear path to margin expansion
    high materiality
    High
    Long-term premium revenue and EPS outlook
    detailed financial outlook through 2029
    high materiality
    High
    Embedded earnings
    $2.50 a share
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Consolidated
    Solid results under current modest expectations.
    $10.2 billion1.6% adjusted pretax margin
    Medicaid
    January 1 rate updates came in as expected, medical cost trend was modestly favorable to expectations. Full year MCR guidance is 92.9%.
    MCR: 92%
    Medicare
    In line with expectations. Successfully completed transition of MMP members to new integrated products (HIDE/FIDE), which are off to a good start. Full year MCR guidance is 94%.
    MCR: 89.8%
    Marketplace
    Slightly higher membership than prior guidance. Profile of membership is as expected, concentrated in the silver tier, with 70% renewal members. Full year MCR guidance is 85.5%.
    MCR: 84%Membership: 305,000

    Operational metrics

    12
    Parent company cash balance
    $213 million
    Q1 FY26

    At the end of the quarter.

    Parent company cash balance target
    more than $600 million
    FY26

    Based on expected subsidiary dividends.

    Days in claims payable
    44modestly lower than typical
    Q1 FY26

    Due to timing of payments at quarter end.

    Medicaid medical cost trend
    7.5%
    FY25

    Observed in 2025, with acuity shift and core utilization impacts diminishing as the year progressed.

    Medicaid low and no utilizers
    7.5 percentage points lowerthan peak pandemic
    Q1 FY26

    Currently below pre-pandemic levels, indicating confidence in no continued acuity shift.

    Marketplace membership renewal rate
    70%
    Q1 FY26

    Renewal members represent a significant portion of the book, contributing to stability.

    Marketplace metallic mix
    50% silver, almost 30% gold, about 20% bronze
    Q1 FY26

    Concentration in silver and gold tiers, with bronze mix up slightly from last year.

    MAPD EPS drag
    $1.00
    FY26

    Expected impact from the MAPD product, which will not recur in 2027.

    MAPD revenue
    $1.2 billion
    FY26

    Revenue associated with the MAPD product being exited.

    Medicare Duals current run rate revenue
    $5.5 billion
    FY26

    Current run rate for D-SNPs, FIDEs, and HIDEs.

    Florida CMS contract total run rate revenue
    $6 billion
    Annual

    Total run rate for the Florida CMS Kids program.

    Medicaid membership attrition
    20,000 decline per quarter
    Q1 FY26

    Expected quarterly decline in Medicaid membership, with 40,000 terminations and 20,000 SAP adds.

    Industry KPIs

    6
    MetricValueDetails
    Utilization trends7.5%%
    Stars rate environmentimproved
    Medical loss care ratio91.1%%
    Membership covered lives by line305,000members
    Adjusted EPS EBITDA leverage guidance$2.35USD
    Medical cost trend vs pricing assumption4%%

    Risks & headwinds

    7
    Challenging medical cost environment

    7.5% medical cost trend in 2025, including 250 bps of acuity shift

    Mitigation: Enhanced medical cost management protocols to address areas of high cost trend.

    Increased Medicaid membership attritionGradually through 2027 and 2028

    Forecasted 6% decline for FY26, up from prior 2% guidance

    Mitigation: Working closely with state partners on administrative requirements; belief that acuity shift impact will be minor.

    Volatility in Marketplace segment

    MCR of 84% in Q1 FY26 (79.5% adjusted)

    Mitigation: Reduced exposure, prioritized margin improvement, concentrated in silver tier, 70% renewal members.

    MAPD product lossesFY26

    $1.00 EPS drag in FY26

    Mitigation: Exiting the product for 2027; exploring transfer to a strategic partner or winding down the business.

    Potential for disruptive regulatory changes in Marketplace2027 pricing cycle

    Not quantified

    Mitigation: Remaining cautious in pricing.

    Unprecedented medical cost inflection in 2025

    Not quantified

    Mitigation: Prudent approach to guidance, waiting for two full quarters of information before updating full-year forecast.

    Uncertainty around Medicaid work requirements and community engagementEmerging gradually through 2027 and 2028

    Not quantified

    Mitigation: Working with state clients on implementation, particularly regarding information needed for termination and exceptions like medical frailty.

    What to watch in Q2 FY26

    5

    Full-year 2026 adjusted EPS guidance update

    After Q2 results
    Currentat least $5
    TargetUpdated guidance reflecting Q1 and Q2 results

    Why it matters

    This will indicate management's updated confidence and actual performance against initial conservative outlook, providing a time-tested base for the second half of the year.

    When we report second quarter results, we will update our full year 2026 guidance to reflect the first and second quarter results, which will provide a time-tested base off of which to project the second half of the year.

    Q&A highlights

    7

    Which states are driving the increased Medicaid attrition, and how does this impact the MLR outlook given the prior acuity shift concerns?

    Increased attrition is primarily in California, Illinois, New York, and Texas, with California influenced by undocumented immigrants. Management believes the acuity shift impact is largely behind them, as low and no utilizers are at their lowest levels, and those leaving are at portfolio averages.

    Right now, we're seeing a lower percentage of low users and no users in our Medicaid population than we ever have, at least since we've been recording it.

    asked by Andrew Mok · answered by Mark Keim

    2 min read7 chapters

    Detailed Narrative

    01

    Q1 Performance Overview

    Molina Healthcare reported adjusted EPS of $2.35 on $10.2 billion of premium revenue for the first quarter, characterizing the results as solid. The consolidated MCR stood at 91.1%, indicating strong operating performance despite a challenging medical cost environment. The company achieved a 1.6% adjusted pretax margin in the quarter.

    02

    Medicaid Medical Cost Trend and Membership

    The Medicaid segment reported a 92% MCR in Q1. Management noted that the January 1 rate updates were as expected, and the medical cost trend was modestly favorable. The 2.5% acuity shift observed in 2025 did not recur, and the annualized Q1 trend suggests it could be better than the 5% full-year assumption. Medicaid membership attrition is now expected to decline by 6% for FY26, up from a prior 2% guidance, primarily due to California, Illinois, New York, and Texas. However, management believes the acuity shift impact is largely behind them, as low and no utilizers are at their lowest levels.

    03

    Medicare Strategy and Performance

    Medicare delivered an 89.8% MCR in Q1, in line with expectations. The company successfully transitioned MMP members to new integrated products (HIDE/FIDE), which are performing better than anticipated. Molina will exit the MAPD product for 2027, which is currently a $1.00 EPS drag. The strategic focus remains on the Duals business, with a positive outlook for 2027 due to an improved Stars profile.

    04

    Marketplace Segment Stability

    The Marketplace segment achieved an 84% MCR in Q1, or approximately 79.5% when adjusted for prior year risk adjustment and program integrity impacts. Membership stands at 305,000, slightly higher than prior guidance. The segment benefits from a stable profile, with 70% renewal members concentrated in the silver tier, leading to greater predictability.

    05

    Prudent Guidance Reaffirmation

    Despite strong first-quarter results, Molina reaffirmed its full-year 2026 adjusted EPS guidance of at least $5 and premium revenue of approximately $42 billion. Management emphasized this as a prudent approach given the early stage of the year and the need for more 'time-tested' results following the volatile medical cost environment of 2025. They plan to update guidance after Q2 results.

    06

    Florida CMS Contract Implementation

    The Florida CMS Kids contract, with a total run rate of $6 billion, is in full implementation mode. Management views this program as financially attractive, expecting it to provide a meaningful addition to embedded earnings over a two-year period. The company is leveraging its expertise in managing high-acuity lives and behavioral costs for this contract.

    07

    M&A Pipeline and Capital Allocation

    Molina indicated a 'replete' M&A pipeline with actionable opportunities, particularly for distressed Medicaid plans. The company remains disciplined in pursuing properties that fit its core strategy. Parent company cash is expected to exceed $600 million by year-end, with a debt-to-capital ratio of 47-48%, targeting the low 40s for a more sustainable level.

    AI-generated summary of the company’s earnings call. Not investment advice.